Metabolic Pharmaceuticals (MBP.AX)'s Obesity Trial Update: First 100 Subjects Complete The Phase 2B Trial Of AOD9604
10/5/2006 11:26:05 AM
More...
|
Metabolic Pharmaceuticals (MBP.AX)'s Neuropathic Pain Drug, ACV1, Enters Phase 2 Clinical Trials
9/28/2006 11:20:32 AM
More...
|
Metabolic Pharmaceuticals (MBP.AX) To Present At The Rodman & Renshaw Techvest 7th Annual Healthcare Conference
11/3/2005 11:51:38 AM
More...
|
Metabolic Pharmaceuticals (MBP.AX) Initiates Recruitment For Phase II-B Clinical Trial Of AOD9604 Obesity Drug
10/19/2005 5:13:22 PM
More...
|
Neuren Pharmaceuticals Limited And Metabolic Pharmaceuticals (MBP.AX) Collaborate To Develop Range Of Nerve Repair Compounds With Support From New Zealand Government
10/19/2005 5:12:56 PM
More...
|
Metabolic Pharmaceuticals (MBP.AX) Appoints New Chief Executive Officer
10/19/2005 5:12:32 PM
More...
|
Metabolic Pharmaceuticals (MBP.AX) Shares Partnering Prospects For AOD9604 For Obesity
10/19/2005 5:12:30 PM
More...
|
Metabolic Pharmaceuticals (MBP.AX) Reports Positive Results From Its Phase 2b Obesity Trial; Fat Burning Pill Effective
10/19/2005 5:12:26 PM
More...
|
Metabolic Pharmaceuticals (MBP.AX) , Circadian Technologies Limited (CIR.AX) Trading Halted Ahead Of Trial Results
10/19/2005 5:12:25 PM
More...
|
Belyea To Step Down As Metabolic Pharmaceuticals (MBP.AX) CEO
10/19/2005 5:12:16 PM
More...
|
|